Becton-Dickinson
This article was originally published in The Gray Sheet
Executive Summary
Expects FDA clearance of the FACSort cell sorting instrument, the FACS Vantage flow cytometer, and the FACSCount CD4, CD8 and CD3 cell counter "literally any day," Diagnostic Sector President Walter Miller tells investors May 11 at the Alex. Brown health care seminar in Baltimore. The devices have been on the market for research use since 1992 ("The Gray Sheet" Jan. 11, 1993, p. 28)